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ABSTRACT
MicroRNAs (miRNAs), a class of small noncoding RNAs that
regulate gene expression, have fundamental roles in biological
processes, including cell differentiation and proliferation. These
small molecules mainly direct either target messenger RNA
(mRNA) degradation or translational repression, thereby func-
tioning as gene silencers. Epithelial cells of the uterine lumen
and glands undergo cyclic changes under the influence of the sex
steroid hormones estradiol-17beta and progesterone. Because
the expression of miRNAs in human endometrium has been
established, it is important to understand whether miRNAs have
a physiological role in modulating the expression of hormonally
induced genes. The studies herein establish concomitant
differential miRNA and mRNA expression profiles of uterine
epithelial cells purified from endometrial biopsy specimens in
the late proliferative and midsecretory phases. Bioinformatics
analysis of differentially expressed mRNAs revealed cell cycle
regulation as the most significantly enriched pathway in the late
proliferative-phase endometrial epithelium (P¼ 5.73 1015). In
addition, the WNT signaling pathway was enriched in the
proliferative phase. The 12 miRNAs (MIR29B, MIR29C, MIR30B,
MIR30D, MIR31, MIR193A-3P, MIR203, MIR204, MIR200C,
MIR210, MIR582-5P, and MIR345) whose expression was
significantly up-regulated in the midsecretory-phase samples
were predicted to target many cell cycle genes. Consistent with
the role of miRNAs in suppressing their target mRNA expression,
the transcript abundance of predicted targets, including cyclins
and cyclin-dependent kinases, as well as E2F3 (a known target of
MIR210), was decreased. Thus, our findings suggest a role for
miRNAs in down-regulating the expression of some cell cycle
genes in the secretory-phase endometrial epithelium, thereby
suppressing cell proliferation.
cell cycle, endometrium, estradiol, microarray, miRNA,
progesterone
INTRODUCTION
Human endometrium undergoes cyclic changes regulated by
the female sex steroid hormones estradiol-17b (E2) and
progesterone (P4). E2 elicits a wave of uterine epithelial cell
proliferation, whereas P4 inhibits this E2-induced epithelial cell
proliferation, promotes differentiation, and has decidualizing
effects on endometrial stroma later in the secretory phase. E2
and P4 act through their cognate nuclear receptor transcription
factors, estrogen receptor 1 and P4 receptor. Results of
experiments using tissue recombinants of uterine epithelium
and stroma, whose estrogen status differ because of inactivat-
ing mutation, suggest that E2 stimulates uterine epithelial cell
proliferation through epithelial estrogen receptor 1 (ESR1) [1].
This contrasts with the situation in mice, in which E2 acts on
epithelial cell proliferation via paracrine influences down-
stream of E2 binding to stromal ESR1 and E2-induced uterine
epithelial cell proliferation is inhibited by P4 actions mediated
via P4 receptor in stroma [1, 2]. Coordinated and synchronized
action of E2 and P4 is essential for controlled proliferation of
endometrium and for uterine receptivity at the time of
implantation. Identification of molecular mechanisms involved
in normal hormonal regulation of human endometrium is
therefore an important step toward understanding molecular
deregulation occurring in pathological situations and may
expose novel therapeutic opportunities.
E2 elicits rapid responses in human and mouse uterus by
activating the so-called canonical cell cycle pathway [2–4]. In
mouse uterus, paracrine signaling through the epithelially
expressed insulin-like growth factor 1 receptor leads to the
activation of the phosphoinositide 3-kinase pathway, followed
by AKT activation that results in inhibitory phosphorylation of
glycogen synthase kinase 3 beta (GSK3B), thereby allowing
accumulation of cyclin D1 in the nucleus, retinoblastoma
protein phosphorylation, and progress of cells through the
restriction point into S-phase [2, 4, 5]. In addition, parallel
activation of DNA replication licensing involving the mini-
chromosome maintenance proteins (MCMs) is necessary for
cell cycle progression into S-phase in mouse endometrial
endometrium [6]. However, in the more complex regenerative
human endometrium, molecular mechanisms underlying its
cyclic changes are not as clearly elucidated. Our previous
investigations on human endometrial biopsy specimens
demonstrated increased epithelial cell expression of markers
of proliferation (antigen identified by monoclonal antibody Ki-
67 [MKI67], proliferating cell nuclear antigen [PCNA], cyclin
A1 [CCNA], and cyclin E [CCNE]) during the proliferative
phase of the menstrual cycle compared with low expression in
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the secretory-phase epithelium [7]. Further inhibition of
GSK3B by lithium chloride in reconstructed human endome-
trial biopsy specimens xenotransplanted into immunocompro-
mised mice resulted in epithelial cell entry into S-phase [8].
These results provide evidence that similar cell cycle regulators
are activated by E2 and inhibited by P4 in human endometrium
as in mouse [7].
miRNAs, a class of small noncoding RNAs, function as
posttranscriptional regulators of gene expression. They bind
through complementary base pairing to the 30 untranslated
regions of their target mRNAs, leading to mRNA degradation
or translational repression [9]. The 50 sequences of miRNAs,
particularly those at nucleotide positions 2 through 7 relative to
the 50 end of miRNA, are important for binding to the target.
Individual targets of miRNAs responsible for the phenotypes
have been proposed in experimental settings, although it is
likely that many miRNAs function through cooperative
regulation of multiple mRNAs [10].
While it is established that miRNAs are expressed in human
endometrium [11, 12], hormonal regulation of miRNAs in the
function of human endometrial epithelium and their role in
differentiation of endometrium into its receptive state remain
unknown. miRNAs have been reported to regulate many
cellular processes that are known to occur during cyclic
changes in endometrium such as cell proliferation and
differentiation [13]. Notably, aberrant miRNA expression has
been associated with human endometrial disorders such as
endometriosis, endometrial hyperplasia, and carcinoma [11, 12,
14, 15]. In addition, miRNAs were recently described as
having a role in postnatal development of mouse uterus and
oviducts [16–18] and in mouse embryo implantation [16, 19,
20]. Taken together, results of previous human and mouse
studies strongly suggest that in human endometrium miRNAs
are likely to have a regulatory function during the physiological
cycle phases.
In the present study, high-density gene expression arrays
were utilized to identify specific miRNAs involved in
hormonal regulation of normal human endometrium by E2
and P4. Well-characterized endometrial biopsy samples were
obtained from eight healthy midreproductive-aged women, and
simultaneous mRNA and miRNA profiles were established for
endometrial epithelial cell preparations either during the late
proliferative phase or midsecretory phase of the menstrual
cycle. The rationale for examining endometrial epithelium
during the time of maximum proliferation (late proliferative
phase) and maximum P4 action (midsecretory phase) was to
elucidate the action of P4 in opposing the effects of estrogen.
The expression profiling of mRNAs and miRNAs in the same
samples allowed us to identify specific mRNAs that may be
posttranscriptionally repressed by miRNAs in human endome-
trial epithelium and to determine some cellular functions and
molecular pathways targeted by these differentially expressed
miRNAs.
MATERIALS AND METHODS
General Participants
This study was approved by The Clinical Investigations/Institutional
Review Board at Albert Einstein College of Medicine and was conducted in
accord with the Declaration of Helsinki for medical research involving human
subjects at the General Clinical Research Center. Written informed consent was
obtained from all participants of this study.
Participants were recruited from the community and were healthy volunteer
women aged 18 through 36 yr with no history of infertility who met the
following criteria: 1) regular 25- to 35-day menstrual cycles, 2) no use of
hormonal contraception within 3 mo, and 3) at least 90% normal weight for
height [21]. Screening done solely for study purposes included history and
physical examination, negative cervical cytology, negative urine pregnancy
test, and normal saline hysterosonogram to rule out any intrauterine pathology.
Sixteen women attended the General Clinical Research Center for endometrial
biopsy, and 14 biopsies were performed. Endometrial biopsy specimens from
eight women, four late proliferative phase and four midsecretory phase, met the
criteria and were analyzed during the course of the study. Characteristics of the
study participants are given in Supplemental Table S1 (available at www.
biolreprod.org).
Endometrial Biopsy Protocol
Endometrial biopsy samplings from the fundal area, as outlined previously
[7], were performed using a Pipelle catheter (Unimar, Inc., Wilton, CT).
Portions of tissues were saved in formalin, 10% vol/vol solution, for
hematoxylin-eosin staining and for histological evaluation. The main portion
of the tissues was further processed for endometrial epithelial cell isolation.
Late proliferative-phase biopsies were performed on the mean 6 SEM
cycle day (CD) 12 6 1 to target the time of maximal endometrial response to
E
2
[22]. Serum E
2
and P
4
samples were obtained on the day of the biopsy; the
sample was excluded if the P
4
level was at least 3.5 ng/ml, indicative of
ovulation [23]. To target the endometrial window of receptivity and maximum
P4 action, secretory biopsy specimens were obtained during the midluteal phase
on CDs 19 through 23. Midsecretory phase was confirmed after biopsy by
serum P
4
level of at least 3.5 ng/ml and by histology [23, 24]. Histological
evaluation of hematoxylin-eosin-stained tissue specimens was performed
blindly by two persons, and cycle phases were assigned according to published
criteria [24]. Histological dating was correlated with CD and serum E2 and P4
levels on the day of endometrial biopsy. Dating of all biopsy specimens was
within a 2-day window from the CD as calculated from the last menstrual
period.
Serum Hormone Assays
Fluoroimmunoassays were used to measure serum E
2
and P
4
levels (Wallac;
PerkinElmer Life and Analytical Sciences, Turku, Finland). This technique was
described previously [7, 25].
Epithelial Cell Isolation
After sampling, endometrial biopsy specimens were transported to the
laboratory in McCoy modified 5A medium on ice. Isolation of epithelial cells
from stromal cells was performed according to the modified protocol by
Satyaswaroop et al. [26]. Briefly, after removal of blood and mucus, the
endometrial biopsy specimen was minced into 1-mm pieces. Minced pieces
were digested with type I collagenase (230 U/mg; Worthington, Lakewood, NJ)
in McCoy modified 5A medium containing 20 000 IU/ml of DNase I (Sigma,
St. Louis, MO) at 378C for 1 h. Collagenase-treated cells were centrifuged and
suspended into RNase-free PBS. The suspension was strained through an 80-
lm nylon mesh, in which epithelial cell microaggregates remain in the mesh,
whereas stromal cells and red blood cells filter through. Isolated epithelial cells
were then washed with RNase-free PBS, centrifuged, and stored in TRIzol
reagent (Invitrogen, Carlsbad, CA) at 808C. Purity of the epithelial cell
preparation was determined by intracellular immunohistochemistry (IHC) using
anti-Pan cytokeratin antibody (clone PCK-26; Sigma) on an isolated epithelial
cell preparation. Epithelial cells were attached and fixed with ethanol onto
Superfrost Plus slides (Thermo Fisher Scientific, Waltham, MA). The fixative
was rinsed off with PBS, and slides were incubated with Triton X-100, 0.3%
vol/vol solution, in PBS for 10 min to permeabilize the membranes, followed
by IHC. The stained cells were observed under light microscopy. The number
of cells showing cytoplasmic cytokeratin staining (only epithelial cells [and not
stromal cells] stain positive for cytokeratin) indicated that the isolation
procedure yielded a greater than 90% pure endometrial epithelial cell
preparation (data not shown).
RNA Extraction
Total RNA and miRNA-enriched RNA were extracted from isolated uterine
epithelial cells using the miRVana miRNA Isolation Kit (Ambion Inc., Austin,
TX) according to the manufacturer’s protocol. RNA yield and quality were
assessed by electrophoresis using the Agilent Technologies Inc. (Santa Clara,
CA) Bioanalyzer 2100 and spectrophotometric analysis.
Sample and Microarray Processing, Human Genome U133
Plus 2.0 Array
Eight endometrial epithelial cell samples were used for microarray analysis.
Forty nanograms of total RNA from each sample was used to generate cDNA,
792 KUOKKANEN ET AL.
D
ow
nloaded from
 w
w
w
.biolreprod.org. 
which was amplified using Ovation RNA Amplification version 2 (product
3100; NuGen Inc., San Carlos, CA). The resulting cDNA was purified using
Research DNA Clean Concentration 25 (Zymo Research Inc., Orange, CA),
and the cDNA quality was assessed using the Bioanalyzer 2100. Following
cDNA amplification and purification, the product was fragmented (50–100 bp)
and labeled with biotin using FL-Ovation cDNA Biotin Module version 2
(product 4200; NuGen Inc.) in preparation for hybridization to Affymetrix
(Santa Clara, CA) GeneChip. We used 3.75 lg of amplified and labeled cDNA
in the hybridization cocktail for GeneChip analysis. Detailed protocols for
sample preparation using Ovation RNA Amplification and labeling protocols
can be found at http://www.nugeninc.com. All samples were subjected to gene
expression analysis using Affymetrix human genome U133 Plus 2.0 arrays.
Hybridization, staining, and washing of all arrays were performed in the
Affymetrix fluidics module. Streptavidin-phycoerythrin stain (SAPE; Molec-
ular Probes, Eugene, OR) is a fluorescent conjugate used to detect hybridized
target sequences. Detection and quantification of target hybridization were
performed using an Affymetrix GeneChip scanner. Data were assessed for array
performance before analysis. The probe-level intensities were processed using
the robust multiarray average method for background correction, normalization,
and log2 transformation of perfect match values [27].
Microarray Data Analysis
mRNA microarray data were analyzed using ArrayAssist 5.0.1 microarray
data analysis software (Stratagene, La Jolla, CA). Data were log2
transformed. Two-tailed Student t-test was performed to compare the
proliferative-phase and midsecretory-phase groups for each transcript, and
fold change was determined. Raw P values were adjusted using the
Benjamini-Hochberg false discovery rate to yield adjusted P values. The
criteria for significance of differentially regulated genes were established as a
greater than 2-fold change with an adjusted P , 0.05. We performed
unsupervised two-way hierarchical clustering analysis (Pearson-centered
distant metrics and centroid linkage rule) on eight samples in each data set
with all probe sets included.
Sample and Microarray Processing, miRCHIP V1 Array
A custom-manufactured Affymetrix GeneChip from Ambion Inc. was
designed for miRNA probes derived from miRBase (http://www.mirbase.org)
and published reports by Asuragen (Austin, TX) [28–31]. Antigenomic probe
sequences were provided by Affymetrix and were derived from a larger set of
controls used on the Affymetrix human exon array for estimating background
signal, as described herein. Other non-miRNA control probes on the array were
designed to lack sequence to the human genome and can be used for spike-in
external reference controls.
Samples for miRNA profiling studies were processed by Asuragen
according to the company’s standard operating procedures. miRNA-enriched
RNA samples were obtained using the miRVana miRNA Isolation Kit and were
provided to Asuragen. The 30 ends of the RNA molecules were tailed and biotin
labeled using the miRVana miRNA Labeling Kit (Ambion Inc.). The kit’s
deoxyribonucleotide triphosphate mixture in the tailing reaction was replaced
with a proprietary mixture containing biotin-modified nucleotides (Perkin
Elmer, Waltham, MA). Hybridization, washing, staining, imaging, and signal
extraction were performed according to Affymetrix-recommended procedures
except that the 203 GeneChip eukaryotic hybridization control cocktail was
omitted from the hybridization. The signal processing implemented for the
Ambion Inc. miRCHIP V1 array was a multistep process and involved probe-
specific signal detection calls, background estimates, and correction. For each
probe, an estimated background value was subtracted that was derived from the
median signal of a set of GC content-matched antigenomic controls. Arrays
within a specific experiment were normalized together according to the
variance stabilization method described by Huber et al. [32]. Detection calls
were based on Wilcoxon rank sum test of miRNA probe signal compared with
the distribution of signals from GC content-matched antigenomic probes. For
statistical hypothesis testing, two-sample t-test with the assumption of equal
variance was applied, and this test defined which probes were considered
significantly differentially expressed based on cutoff values of P , 0.05 and a
greater than 2-fold or less than 2-fold difference in expression. To reduce the
false discovery rate of miRNAs, we excluded miRNAs whose expression was
detected in fewer than three of four specimens in either the late proliferative-
phase group or the midsecretory-phase group. We performed unsupervised two-
way hierarchical clustering analysis (Pearson-centered distant metrics and
centroid linkage rule) on eight samples in each data set with differentially
expressed miRNAs (.1.5-fold or ,1.5-fold difference in expression with P ,
0.05). A heatmap was generated, and the dendrogram shows relationships
between specimens.
Quantitative Real-Time PCR
One microgram of total RNA from each sample was used for the RT
reaction to generate cDNA using SuperScript II RT (Invitrogen) and random
hexamers. Quantitative real-time PCR was performed in triplicate using SYBR
Green PCR Master Mix (Applied Biosystems, Norwalk, CT) according to the
manufacture’s instructions and using an ABI Prism 7900HT (Amersham-
Pharmacia, Piscataway, NJ). The PCR primers were designed to be intron
spanning and to amplify 68- to 300-bp fragments (Supplemental Table S2).
mRNA expression of TGF3B was analyzed using TaqMan assay (Applied
Biosystems). The data were normalized to expression levels of the
housekeeping gene GAPDH, and the relative expression was calculated using
the 2DDCT method [33].
TaqMan miRNA assays (Applied Biosystems) were used to quantify the
expression of miRNAs according to the manufacturer’s instructions. The mean
cycle threshold (CT) value was determined from four PCR replicates. The data
were normalized to expression levels of SNORD48 (also known as RNU48).
Relative gene expression of the late proliferative-phase vs. midsecretory-phase
samples was assessed using the 2DDCT method [33].
Bioinformatics
The Database for Annotation, Visualization and Integrated Discovery
(DAVID 2008; http://david.abcc.ncifcrf.gov) and Ingenuity Pathway Analysis
software (IPA 7.6; Ingenuity Systems, Redwood City, CA) were used to
identify enriched cellular and molecular functions among differentially
expressed gene transcripts. DAVID 2008 and the Gene Ontology project
(http://www.geneontology.org) were used to classify differentially expressed
genes into functionally related groups of genes. Target genes of miRNAs were
predicted using the following algorithms: miRanda (http://www.ebi.ac.uk/ena/),
PicTar (http://pictar.mdc-berlin.de/), and TargetScan (http://www.targetscan.
org).
RESULTS
Endometrial biopsy specimens were obtained from eight
midreproductive-aged women. The ages of these women
ranged from 19 to 36 yr (mean age, 29.0 yr) in the late
proliferative-phase group and from 22 to 30 yr (mean age, 24.3
yr) in the midsecretory-phase group. The mean 6 SEM serum
E2 levels were 170.43 6 36.17 pg/ml in the late proliferative-
phase group and 121.55 6 43.56 pg/ml in the midsecretory-
phase group. The mean 6 SEM serum P4 levels were 0.39 6
0.19 ng/ml in the late proliferative-phase group and 12.20 6
1.20 ng/ml in the midsecretory-phase group. General data on
the women in the study are given in Supplemental Table S1.
Late Proliferative-Phase and Midsecretory-Phase
Endometrial Epithelia Exhibit Distinct miRNA and mRNA
Expression Profiles
To establish miRNA and mRNA profiles of endometrial
epithelium, microarray analyses were performed on sets of four
late proliferative-phase and four midsecretory-phase epithelial
samples of endometrium. To identify the most informative set
of differentially expressed genes between the late proliferative-
phase and midsecretory-phase groups, we ranked each gene by
the probability that the mean of its expression values is
statistically distinct between the two groups using Student t-
test. We focused our attention on genes meeting our designated
criteria of P, 0.05 and a greater than 2-fold or less than 2-fold
change. In this fashion, we identified 3244 differentially
expressed mRNAs between the late proliferative-phase vs.
midsecretory-phase epithelium of endometrium; 2206 genes
were up-regulated, and 1038 genes were down-regulated
(Supplemental Fig. S1). Among human miRNAs on miRCHIP
V1, 49 microarray probes were differentially expressed
between the two groups (24 are published miRNAs, and 25
represent novel predicted miRNA sequences). The transcript
abundance of 12 published miRNAs was increased and of 12
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published miRNAs decreased in the late proliferative-phase vs.
midsecretory-phase epithelial samples (Table 1).
To visually assess differentially expressed gene profiles, we
performed unsupervised hierarchical clustering analysis sepa-
rately for mRNAs and miRNAs using eight well-characterized
endometrial epithelial samples. Dendrograms show complete
segregation of the late proliferative-phase and midsecretory-
phase samples into two groups based on their mRNA (Fig. 1A)
and miRNA (Fig. 1B) expression patterns. Notably, all four
late proliferative-phase samples cluster robustly together, as do
the midsecretory-phase samples, even when the expression data
from all of the more than 48 000 probes of the human genome
U133 Plus 2.0 array are utilized for the analysis. These data
suggest that the late proliferative-phase endometrial epithelium
exhibits unique mRNA and miRNA expression signatures
compared with the midsecretory-phase endometrial epithelium.
Late Proliferative-Phase Endometrial Epithelium Expresses
Increased Transcript Abundance of Cell Cycle Regulators
Next, we analyzed the transcriptome of the late proliferative-
phase endometrial epithelium using the DAVID 2008 bioinfor-
matics program. Genes that showed significantly increased
transcript abundance in the late proliferative-phase samples were
enriched for the following functional Gene Ontology groups:
cell cycle (Gene Ontology enrichment score, 25.32; P ¼ 7.5 3
1029), cell cycle phase, M-phase, mitosis, cell division,
regulation of cell cycle, and DNA replication. Also, bioinfor-
matics analysis revealed cell cycle regulation as the most
significantly enriched functional pathway in the late prolifera-
tive-phase endometrial epithelium (KEGG pathway [http://
www.genome.jp/kegg/pathway.html] cell cycle, P ¼ 5.7 3
1015) (Fig. 2) [34, 35]. These results are in agreement with a
previous global gene expression study [36] of the proliferative-
phase vs. secretory-phase total endometrium. Differentially
expressed transcripts were uploaded to the IPA 7.6 database to
explore for enriched biological functions and pathways. As
previously reported in investigations using whole endometrial
specimens [36], the biological functions of cell cycle, DNA
replication, recombination and repair, and cellular growth and
proliferation were differentially regulated between late prolifer-
ative-phase and midsecretory-phase endometrial epithelium (Fig.
3). The enriched canonical pathways were mitotic roles of polo-
like kinases, WNT/b-catenin and sonic hedgehog signaling, cell
cycle regulation by the B-cell translocation gene (BTG) proteins,
and checkpoint cell cycle regulation (G1/S and G2/M).
miRNA Gene Signatures of Late Proliferative-Phase
and Midsecretory-Phase Endometrial Epithelia
We then explored the specific miRNAs that showed
differential expression between the late proliferative-phase
and midsecretory-phase epithelial cell samples. As summarized
in Table 1, the expression of several miRNAs was altered in
epithelial cells of endometrium between the two physiological
phases of the menstrual cycle. Among miRNAs with lower
transcript level in the late proliferative-phase samples than in
the midsecretory-phase samples, MIR210 and MIR193A-3P
were the most highly decreased by microarray analysis. The
other notable miRNAs in this list are MIR29B and MIR29C,
which belong to the MIR29 miRNA cluster, as well as MIR30B
and MIR30D, which belong to the MIR30 miRNA cluster.
Among significantly up-regulated late proliferative-phase
miRNAs were MIR503 and MIR450, which belong to the
MIR542-3P miRNA cluster.
Using quantitative real-time PCR, we validated the
expression of select miRNAs. As shown in Figure 4, the
expression level of MIR210, MIR29B, MIR29C, MIR30B,
MIR30D, MIR193A-3P, MIR200C, and MIR31 was signifi-
cantly decreased in the late proliferative-phase vs. midsecre-
tory-phase endometrial epithelium, thus validating our
miRCHIP V1 data. Among up-regulated miRNAs, the
expression of MIR503 showed significantly increased expres-
sion in the late proliferative-phase samples than in the
midsecretory-phase samples. The expression levels of
MIR405, MIR542-3P, MIR214, and MIR134 did not reach
statistical significance, although the trend of increased
expression level in the late proliferative-phase vs. midsecre-
tory-phase endometrial epithelium was consistent with the
microarray data. Surprisingly, MIR214 demonstrated the
highest fold change expression between the two groups by
microarray analysis, but quantitative real-time PCR did not
validate this result. MIR222 showed 2.4-fold and 1.7-fold
increases in the transcript abundance by miRNA microarray
and quantitative real-time PCR, respectively.
Cell Cycle Genes Are Targeted by miRNAs Exhibiting
Increased Transcript Abundance in Midsecretory-Phase
Endometrial Epithelium
For further study, we investigated miRNAs whose transcript
abundance was increased in the midsecretory-phase samples
compared with the late proliferative-phase samples, as these
TABLE 1. MicroRNAs differentially expressed in the late proliferative phase compared to the midsecretory phase endometrial epithelium.
Down-regulated in late proliferative endometrium Up-regulated in midsecretory endometrium
miRNA gene Accession no.a Fold changeb P value miRNA gene Accession no.a Fold changeb P value
MIR210 MIMAT0000267 7.1 0.0003 MIR214 MIMAT0000271 4 0.02
MIR193A-3P MIMAT0000459 5.2 0.0002 MIR503 MIMAT0002874 3.6 0.007
MIR345 MIMAT0000772 3.3 0.002 MIR134 MIMAT0000447 3.1 0.03
MIR29B MIMAT0000100 2.8 0.0007 MIR450 MIMAT0001545 3 0.003
MIR29C MIMAT0000681 2.6 0.005 MIR382 MIMAT0000737 2.6 0.03
MIR30B MIMAT0000420 2.6 0.01 MIR376A MIMAT0003386 2.6 0.04
MIR204 MIMAT0000265 2.6 0.04 MIR369-5P MIMAT0001621 2.4 0.006
MIR203 MIMAT0000264 2.5 0.000086 MIR222 MIMAT0000279 2.4 0.04
MIR582-5P MIMAT0003247 2.3 0.01 MIR370 MIMAT0000722 2.3 0.01
MIR30D MIMAT0000245 2.2 0.005 MIR542-3P MIMAT0003389 2.2 0.04
MIR200C MIMAT0000617 2.1 0.004 MIR105 MIMAT0000102 2.1 0.01
MIR31 MIMAT0000089 2.1 0.02 MIR127 MIMAT0000446 2.1 0.01
a The accession number is for the mature miRNA sequence.
b MicroRNAs significantly (P , 0.05) differentially regulated (fold change 6 .2.0) as determined by Student t-test from microarray analysis of the late
proliferative phase epithelial samples as compared to the midsecretory epithelial samples are listed in order of the fold change.
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miRNAs are likely to negatively modulate the expression of
cell cycle regulators. Using bioinformatics online sites
(miRanda, TargetScan, and PicTar), we identified predicted
target mRNAs of these specific miRNAs. Predicted targets
were then further characterized using Gene Ontology analysis
(DAVID 2008) to identify targets that are functionally involved
in the cell cycle pathway (KEGG pathway). Table 2 gives
predicted cell cycle targets of each miRNA. With the mRNA
expression results, it was striking to note that the transcript
abundance of 19 predicted cell cycle genes was decreased in
the midsecretory-phase samples by the mRNA array data, as
would be expected if their expression was modulated by the
respective miRNAs. Quantitative real-time PCR of these 19
cell cycle genes robustly validated results from the array (Fig.
5). We previously reported increased transcript abundance of
cyclin A, cyclin E, and MCM2 in the late proliferative-phase
vs. midsecretory-phase laser capture microdissected glandular
epithelial samples, thus validating the expression of these
transcripts in independent biological repeats [7].
DISCUSSION
In the present study, we demonstrate that the mRNA
transcript profile of the late proliferative-phase endometrial
epithelium is enriched for genes involved in cell cycle
regulation. Moreover, we show that miRNAs are differentially
expressed during the physiological phases of the menstrual
cycle, suggesting that they are hormonally regulated in human
endometrial epithelium. miRNAs that show increased tran-
script abundance during the midsecretory phase are predicted
to target several cell cycle regulators. Consistent with the
miRNA data, the transcript levels of several of these cell cycle
regulators are lower during the midsecretory phase than during
the late proliferative phase. These results suggest that miRNAs
FIG. 1. Dendrogram and unsupervised hierarchical clustering. Expression data from all mRNA probes (A) and expression data from differentially
expressed miRNAs showing a greater than 1.5-fold or less than 1.5-fold change in expression with P , 0.05 (B) in four late proliferative-phase (pp) and
four midsecretory-phase (sp) samples. The top dendrogram shows the relationship between the samples based on gene expression patterns. Hierarchical
clustering analyses robustly separate the late proliferative-phase samples from the midsecretory-phase samples and assign each sample to the correct
menstrual cycle phase. The expression intensity of each gene in each sample varies from high (red) to low (green).
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may posttranscriptionally down-regulate the expression of cell
cycle genes, thereby suppressing cell cycle progression and cell
proliferation in human secretory-phase endometrial epithelium.
Our global mRNA and miRNA microarray analysis yielded
specific gene expression signatures for the late proliferative-
phase and midsecretory-phase epithelial samples. To our
knowledge, this is the first study to demonstrate differential
expression profiles of miRNAs in human endometrial epithe-
lium according to menstrual cycle phases in midreproductive-
aged women who had been extensively screened for hormonal
status and absence of intrauterine pathologies. Grouping of
endometrial samples based solely on their mRNA expression
profiles and histological menstrual cycle stage has been
previously described for entire endometrial samples, including
epithelium and stroma [36]. Consistent with previous expres-
sion profiles of whole endometrium [36, 38], our present data
define the proliferative-phase transcriptome as one that is
characterized by cell cycle regulatory functions reflecting the
active mitogenic state of cells. Furthermore, two separate
pathway analysis programs identified cell cycle regulation as
the most significantly enriched pathway. Also, it is notable that
our findings of increased transcript levels of DNA replication
licensing members (such as MCM2, MCM3, MCM4, MCM5,
MCM6, MCM7, and origin recognition complex proteins) in
the late proliferative-phase samples are in agreement with prior
expression results [39]. These data suggest that, in addition to
cell cycle regulation, DNA replication licensing is likely
another key regulatory point in hormonal regulation of
epithelial cell proliferation in human endometrium, as
previously demonstrated in mouse endometrium [6]. Further-
more, bioinformatics analysis of the mRNA array data
indicates that WNT/b-catenin signaling, previously implicated
in hormonal regulation of the proliferative-phase and secretory-
phase endometrium [36, 38], is a significantly regulated
canonical pathway in endometrial epithelium across the
menstrual cycle. Specifically, we observed up-regulation of
WNT ligands (WNT5A and WNT7A) and lymphoid enhance
binding factor 1 (LEF1) in the late proliferative-phase vs.
midsecretory-phase endometrial epithelium, whereas the tran-
script abundance of WNT inhibitors dikkopf homolog (DKK1)
and forkhead box O1 (FOXO1) was increased in the
midsecretory-phase epithelial cells. Notably, using in situ
FIG. 2. Transcripts regulating the mammalian cell cycle are up-regulated in the proliferative-phase endometrial epithelium. Genes with a greater than 2-
fold increase in transcript abundance with P , 0.05 in the late proliferative-phase samples compared with the midsecretory-phase samples from the
human genome U133 Plus 2.0 arrays are indicated in purple boxes and represent 38 up-regulated genes. Green and white boxes indicate cell cycle genes
that showed no differential expression between the late proliferative-phase samples compared with the midsecretory-phase samples. The diagram is based
on the cell cycle pathway in the KEGG pathway database [34, 35].
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hybridization, Tulac et al. [40] have shown that WNT7A
mRNA expression is restricted exclusively to luminal epithe-
lium of human endometrium. Furthermore, using WNT-
activated Ishikawa cells, Wang et al. [41] recently demonstrat-
ed that P4 induction of DKK1 and FOXO1 resulted in
inhibition of WNT signaling. While WNT signaling is a well-
known pathway in hormonal regulation of human endometrium
based on gene expression data [36, 38] and from investigations
of mouse uterus [1, 42], we recognize that molecular
mechanisms of sex steroid regulation remain obscure. Because
these are secreted molecules, they may mediate epithelial and
stromal interactions, mediating hormonal effects on endome-
trial cells.
Most important, specific miRNAs with increased transcript
abundance in the midsecretory-phase samples were predicted to
target several genes involved in DNA replication licensing and
in cell cycle regulation (Table 2). For example, key cell cycle
regulators, cyclins and their partners cyclin-dependent kinases
(CDKs), were predicted to be targeted by MIR31, MIR29B,
MIR29C, MIR30B, and MIR30D, whereas the expression of
MCM2 was predicted to be regulated by MIR31, MIR30B, and
MIR30D and that of MCM4 by MIR210 (Table 2). MIR210 has
been reported to down-regulate the expression of E2F
transcription factor 3 (E2F3) [37], an important transcription
factor that induces the expression of cell cycle-regulated genes
and promotes cell cycle progression. The transcript levels of
several putative cell cycle targets were decreased in the
midsecretory-phase samples, as would be expected if their
expression was down-regulated by miRNAs, whereas the
transcript levels of others were unchanged. For instance, cell
division cycle 7 (CDC7) was predicted to be targeted by at
least two miRNAs, yet its mRNA level showed no significant
change between the cycle phases. However, miRNA regulation
of this target may occur through translational repression, in
which case only the protein level would be altered. Of note is
that the same miRNAs that are putative regulators of genes
involved in DNA replication licensing may also regulate
cyclins and CDKs. Recently, tumor-suppressive miRNAs
(MIR16 and MIR34A families) have been reported to modulate
the expression of multiple cell cycle regulators [43–45]. To this
end, our observations (although only based on gene expression
data) perfectly fit a view of miRNA-mediated regulation of
gene expression in which a single miRNA can regulate
multiple genes that have related functions.
Two miRNAs, MIR221 and MIR222, are known to
negatively regulate the expression of CDK inhibitor 1B
FIG. 3. Transcripts mediating cell cycle
regulation are differentially regulated be-
tween the late proliferative-phase vs. mid-
secretory-phase endometrial epithelium.
Differentially expressed transcripts were
subjected to bioinformatics analysis using
IPA 7.6. A) Most significantly enriched
groups relating to molecular and cellular
functions. B) Most significantly enriched
canonical signaling pathways. The total
number of genes in a pathway is boldfaced.
For each pathway, the percentage of genes
that are of decreased (green) or increased
(red) transcript abundance is indicated at
the top. Portions of pathway genes that are
not significantly changed are also shown
(white). The yellow square for each pathway
indicates –log(P value). The yellow arrow
indicates P ¼ 0.05.
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(CDKN1B, also known as p27/KIP1) by suppressing transla-
tion of mRNA into protein [46]. CDKN1B is an important cell
cycle inhibitor, and it executes this function by binding and
inhibiting CCNE/CDK2 and CCNA/CDK2 complexes in early
G1-phase [47]. Recent IHC investigations by Niklaus et al. [7]
demonstrated that CDKN1B protein expression is lower in
epithelial cells of human endometrium in the late proliferative
phase than in the midsecretory phase. Herein, we observed
increased transcript abundance of MIR222 in the late
proliferative-phase samples, whereas no significant change
was found in CDKN1B mRNA level, as expected. Qian et al.
[48] recently reported down-regulation of MIR222 expression
in endometrial stromal cells, permitting CDK inhibitor 1C
(CDKN1C, also known as p57/KIP2) expression and thereby
suppressing stromal cell proliferation in vitro. Increased
expression of MIR221 and MIR222 has been observed in
several human cancers, supporting their function as oncogenes
[49–51]. Notably, aberrant MIR221 expression was recently
reported in atypical endometrial hyperplasia and endometrial
cancer [12]. Although further validation studies are needed, our
results suggest that MIR222 may have a cell cycle regulatory
role in human endometrial epithelium.
A prior study [11] explored differential expression of
miRNAs in human endometrium according to menstrual cycle
phases but failed to show any significant differences in miRNA
profiles. Of note is that this study limited research to entire
endometrium, including glandular and luminal epithelium, as
well as stroma, as the study was primarily designed to explore
the role of miRNAs in endometriosis. There is evidence that
uterus is a complex tissue comprising different resident cell
types that respond differently to hormonal exposure [7]. Two
markers of proliferation, MKI67 and MCM2, are expressed at
peak levels in luminal and glandular epithelial cells during the
proliferative phase, whereas the expression of these prolifer-
ative markers in stromal cells shows much less change across
the two cycle phases [7, 52]. Collectively, these findings
indicate that responses to sex steroid hormones are cell-type
specific; therefore, to understand the mechanism of action of
these hormones, it is essential to study responses in particular
cell types. However, separating the two cellular compartments
for molecular studies precludes any opportunities to investigate
the mechanistic basis of epithelial and stromal cell interactions
and thus paracrine influences in mediating hormonal effects on
these two cell types.
Identification of protein-coding genes that are regulated by a
specific miRNA has proved difficult, despite development of
computational approaches to predict miRNA targets. The
ability to identify target mRNA is further hampered by the fact
that only partial complementary sequence between miRNA and
the 30 untranslated regions of target mRNA is needed and that
target selectivity of miRNAs may depend on the cellular
environment. To circumvent some of these difficulties, we
studied the expression profiles of miRNA and mRNA in the
same epithelial cell samples of endometrium to identify
differentially expressed miRNAs and to investigate the
influence of these miRNAs on putative target gene transcript
FIG. 4. Expression of selected up-regulated (A) and down-regulated (B)
miRNAs in the late proliferative-phase endometrial samples relative to the
midsecretory-phase endometrial samples by quantitative real-time PCR.
All samples were normalized to RNU48. Relative gene expression of the
late proliferative-phase vs. midsecretory-phase samples was assessed
using the 2DDCT method [33]. Data shown indicate relative expression of
the late proliferative-phase samples (gray bar) with respect to the
midsecretory-phase samples (black bars) set to 1. The error bars show
the SEM. *P , 0.05, **P , 0.01, and ***P , 0.001.
FIG. 5. Quantitative real-time PCR validates gene expression array data
from the cell cycle regulation ontological group. Nineteen genes were
validated as differentially regulated cell cycle members from the human
genome U133 Plus 2.0 array using quantitative real-time PCR. All samples
were normalized to the housekeeping gene GAPDH. Data shown indicate
relative expression of the late proliferative-phase samples (gray bar) with
respect to the midsecretory-phase samples (black bars) set to 1. The error
bars show the SEM. ***P , 0.001, **P , 0.01, and *P , 0.05.
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levels. This approach can be successful if miRNAs of interest
affect the transcript abundance of target mRNAs but fails if the
target genes are regulated only by translational suppression.
Most miRNAs are believed to negatively regulate their target
gene expression by causing degradation of mRNA transcripts
or translational repression, which would lead to an inverse
expression relationship between miRNA and its target.
However, this relationship may be more complex than
previously thought, miRNAs were recently described as being
able to activate translation of their targets [53].
The array data presented herein revealed several miRNAs
whose transcript abundance is significantly increased in
endometrial epithelium during the midsecretory phase com-
pared with the late proliferative phase. Prediction analysis
identified many cell cycle regulators as putative target mRNAs
of these up-regulated miRNAs. These results suggest a new
level of gene expression regulation that may be involved in
hormonal regulation of epithelial cell proliferation in human
endometrium by E2 and P4. Ongoing studies are focusing on
validating the true cell cycle targets of differentially expressed
miRNAs and on defining the functions of these miRNAs in
human endometrial epithelium.
ACKNOWLEDGMENTS
We thank Drs. Andy Brooks and Qi Wang in the Bionomics Research
and Technology Center, University of Medicine and Dentistry of New
Jersey, for excellent technical assistance with Affymetrix arrays and data
analysis. In addition, we thank Ms. Donna Gerardi for support with figure
design. We also thank the women who participated in the study.
REFERENCES
1. Kurita T, Medina R, Schabel AB, Young P, Gama P, Parekh TV, Brody J,
Cunha GR, Osteen KG, Bruner-Tran KL, Gold LI. The activation
function-1 domain of estrogen receptor alpha in uterine stromal cells is
required for mouse but not human uterine epithelial response to estrogen.
Differentiation 2005; 73:313–322.
2. Zhu L, Pollard JW. Estradiol-17beta regulates mouse uterine epithelial cell
proliferation through insulin-like growth factor 1 signaling. Proc Natl
Acad Sci U S A 2007; 104:15847–15851.
3. Guzeloglu Kayisli O, Kayisli UA, Luleci G, Arici A. In vivo and in vitro
regulation of Akt activation in human endometrial cells is estrogen
dependent. Biol Reprod 2004; 71:714–721.
4. Tong W, Pollard JW. Progesterone inhibits estrogen-induced cyclin D1
and cdk4 nuclear translocation, cyclin E- and cyclin A-cdk2 kinase
activation, and cell proliferation in uterine epithelial cells in mice. Mol
Cell Biol 1999; 19:2251–2264.
5. Chen B, Pan H, Zhu L, Deng Y, Pollard JW. Progesterone inhibits the
estrogen-induced phosphoinositide 3-kinase–.AKT–.GSK-3beta–
.cyclin D1–.pRB pathway to block uterine epithelial cell proliferation.
Mol Endocrinol 2005; 19:1978–1990.
6. Pan H, Deng Y, Pollard JW. Progesterone blocks estrogen-induced DNA
synthesis through the inhibition of replication licensing. Proc Natl Acad
Sci U S A 2006; 103:14021–14026.
7. Niklaus AL, Aubuchon M, Zapantis G, Li P, Qian H, Isaac B, Kim MY,
Adel G, Pollard JW, Santoro NF. Assessment of the proliferative status of
epithelial cell types in the endometrium of young and menopausal
transition women. Hum Reprod 2007; 22:1778–1788.
8. Polotsky AJ, Zhu L, Santoro N, Pollard JW. Lithium chloride treatment
induces epithelial cell proliferation in xenografted human endometrium.
Hum Reprod 2009; 24:1960–1967.
9. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function.
Cell 2004; 116:281–297.
10. Lim LP, Lau NC, Garrett-Engele P, Grimson A, Schelter JM, Castle J,
Bartel DP, Linsley PS, Johnson JM. Microarray analysis shows that some
microRNAs downregulate large numbers of target mRNAs. Nature 2005;
433:769–773.
11. Ohlsson Teague EM, Van der Hoek KH, Van der Hoek MB, Perry N,
Wagaarachchi P, Robertson SA, Print CG, Hull LM. MicroRNA-regulated
pathways associated with endometriosis. Mol Endocrinol 2009; 23:265–
275.
12. Boren T, Xiong Y, Hakam A, Wenham R, Apte S, Wei Z, Kamath S, Chen
DT, Dressman H, Lancaster JM. MicroRNAs and their target messenger
RNAs associated with endometrial carcinogenesis. Gynecol Oncol 2008;
110:206–215.
13. Bueno MJ, de Castro IP, Malumbres M. Control of cell proliferation
pathways by microRNAs. Cell Cycle 2008; 7:3143–3148.
14. Pan Q, Luo X, Toloubeydokhti T, Chegini N. The expression profile of
micro-RNA in endometrium and endometriosis and the influence of
ovarian steroids on their expression. Mol Hum Reprod 2007; 13:797–806.
15. Burney RO, Hamilton AE, Aghajanova L, Vo KC, Nezhat CN, Lessey
BA, Giudice LC. MicroRNA expression profiling of eutopic secretory
endometrium in women with versus without endometriosis. Mol Hum
Reprod 2009; 15:625–631.
16. Gonzalez G, Behringer RR. Dicer is required for female reproductive tract
development and fertility in the mouse. Mol Reprod Dev 2009; 76:678–
688.
17. Nagaraja AK, Andreu-Vieyra C, Franco HL, Ma L, Chen R, Han DY, Zhu
H, Agno JE, Gunaratne PH, DeMayo FJ, Matzuk MM. Deletion of Dicer
in somatic cells of the female reproductive tract causes sterility. Mol
Endocrinol 2008; 22:2336–2352.
18. Hong X, Luense LJ, McGinnis LK, Nothnick WB, Christenson LK.
Dicer1 is essential for female fertility and normal development of the
female reproductive system. Endocrinology 2008; 149:6207–6212.
19. Hu SJ, Ren G, Liu JL, Zhao ZA, Yu YS, Su RW, Ma XH, Ni H, Lei W,
Yang ZM. MicroRNA expression and regulation in mouse uterus during
embryo implantation. J Biol Chem 2008; 283:23473–23484.
20. Chakrabarty A, Tranguch S, Daikoku T, Jensen K, Furneaux H, Dey SK.
MicroRNA regulation of cyclooxygenase-2 during embryo implantation.
Proc Natl Acad Sci U S A 2007; 104:15144–15149.
21. Company MLI. New weight standards for men and women. Stat Bull
Metrop Life Found 1983; 64:1–4.
22. Lessey BA, Killam AP, Metzger DA, Haney AF, Greene GL, McCarty
KSJ. Immunohistochemical analysis of human uterine estrogen and
progesterone receptors throughout the menstrual cycle. J Clin Endocrinol
Metab 1988; 67:334–340.
23. Israel R, Mishell DR, Stone SS, Thorneycroft IH, Moyer DL. Single luteal
phase serum progesterone assay as an indicator of ovulation. Am J Obstet
Gynecol 1972; 112:1043–1046.
24. Noyes RW, Haman JO. Accuracy of endometrial dating: correlation of
endometrial dating with basal body temperature and menses. Fertil Steril
1953; 4:504–517.
25. Santoro N, Isaac B, Neal-Perry G, Weingart L, Nussbaum A, Thakur S,
Jinnai H, Khosla N, Barad D. Impaired folliculogenesis and ovulation in
older reproductive aged women. J Clin Endocrinol Metab 2003; 88:5502–
5509.
26. Satyaswaroop PG, Fleming H, Bressler RS, Gurpide E. Human
endometrial cancer cell cultures for hormonal studies. Cancer Res 1978;
38:4367–4375.
27. Gautier L, Cope L, Bolstad BM, Irizarry RA. affy: Analysis of Affymetrix
GeneChip data at the probe level. Bioinformatics 2004; 20:307–315.
28. Xie X, Lu J, Kulbokas EJ, Golub TR, Mootha V, Lindblad-Toh K, Lander
ES, Kellis M. Systematic discovery of regulatory motifs in human
promoters and 30 UTRs by comparison of several mammals. Nature 2005;
434:338–345.
29. Berezikov E, Guryev V, van de Belt J, Wienholds E, Plasterk RH, Cuppen
E. Phylogenetic shadowing and computational identification of human
microRNA genes. Cell 2005; 120:21–24.
30. Cummins JM, He Y, Leary RJ, Pagliarini R, Diaz LA Jr, Sjoblom T, Barad
O, Bentwich Z, Szafranska AE, Labourier E, Raymond CK, Roberts BS, et
al. The colorectal microRNAome. Proc Natl Acad Sci U S A 2006; 103:
3687–3692.
31. Bentwich I, Avniel A, Karov Y, Aharonov R, Gilad S, Barad O, Barzilai
A, Einat P, Einav U, Meiri E, Sharon E, Spector Y, et al. Identification of
hundreds of conserved and nonconserved human microRNAs. Nat Genet
2005; 37:766–770.
32. Huber W, von Heydebreck A, Sultmann H, Poustka A, Vingron M.
Variance stabilization applied to microarray data calibration and to the
quantification of differential expression. Bioinformatics 2002; 18(suppl 1):
S96–S104.
33. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using
real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods
2001; 25:402–408.
34. Talbi S, Hamilton AE, Vo KC, Tulac S, Overgaard MT, Dosiou C, Le
Shay N, Nezhat CN, Kempson R, Lessey BA, Nayak NR, Giudice LC.
Molecular phenotyping of human endometrium distinguishes menstrual
cycle phases and underlying biological processes in normo-ovulatory
women. Endocrinology 2006; 147:1097–1121.
35. Giannakakis A, Sandaltzopoulos R, Greshock J, Liang S, Huang J,
800 KUOKKANEN ET AL.
D
ow
nloaded from
 w
w
w
.biolreprod.org. 
Hasegawa K, Li C, O’Brien-Jenkins A, Katsaros D, Weber BL, Simon C,
Coukos G, et al. miR-210 links hypoxia with cell cycle regulation and is
deleted in human epithelial ovarian cancer. Cancer Biol Ther 2008; 7:255–
264.
36. Dennis G Jr, Shernan BT, Hosack DA, Yang J, Gao W, Lane HC,
Lempicki RA. DAVID: Database for Annotation, Visualization, and
Integrated Discovery. Genome Biol 2003; 4:eP3.
37. Huang DW, Sherman BT, Lempicki RA. Systematic and integrative
analysis of large gene lists using DAVID bioinformatics resources. Nat
Protoc 2009; 4:44–57.
38. Borthwick JM, Charnock-Jones DS, Tom BD, Hull ML, Teirney R,
Phillips SC, Smith SK. Determination of the transcript profile of human
endometrium. Mol Hum Reprod 2003; 9:19–33.
39. Burney RO, Talbi S, Hamilton AE, Vo KC, Nyegaard M, Nezhat CR,
Lessey BA, Giudice LC. Gene expression analysis of endometrium reveals
progesterone resistance and candidate susceptibility genes in women with
endometriosis. Endocrinology 2007; 148:3814–3826.
40. Tulac S, Nayak NR, Kao LC, Van Waes M, Huang J, Lobo S, Germeyer
A, Lessey BA, Taylor RN, Suchanek E, Giudice LC. Identification,
characterization, and regulation of the canonical Wnt signaling pathway in
human endometrium. J Clin Endocrinol Metab 2003; 88:3860–3866.
41. Wang Y, Hanifi-Moghaddam P, Hanekamp EE, Kloosterboer HJ, Franken
P, Veldscholte J, van Doorn HC, Ewing PC, Kim JJ, Grootegoed JA,
Burger CW, Fodde R, et al. Progesterone inhibition of Wnt/beta-catenin
signaling in normal endometrium and endometrial cancer. Clin Cancer Res
2009; 15:5784–5793.
42. Hou X, Tan Y, Li M, Dey SK, Das SK. Canonical Wnt signaling is critical
to estrogen-mediated uterine growth. Mol Endocrinol 2004; 18:3035–
3049.
43. Liu Q, Fu H, Sun F, Zhang H, Tie Y, Zhu J, Xing R, Sun Z, Zheng X.
miR-16 family induces cell cycle arrest by regulating multiple cell cycle
genes. Nucleic Acids Res 2008; 36:5391–5404.
44. Linsley PS, Schelter J, Burchard J, Kibukawa M, Martin MM, Bartz SR,
Johnson JM, Cummins JM, Raymond CK, Dai H, Chau N, Cleary M, et al.
Transcripts targeted by the microRNA-16 family cooperatively regulate
cell cycle progression. Mol Cell Biol 2007; 27:2240–2252.
45. Sun F, Fu H, Liu Q, Tie Y, Zhu J, Xing R, Sun Z, Zheng X.
Downregulation of CCND1 and CDK6 by miR-34a induces cell cycle
arrest. FEBS Lett 2008; 582:1564–1568.
46. le Sage C, Nagel R, Egan DA, Schrier M, Mesman E, Mangiola A, Anile
C, Maira G, Mercatelli N, Ciafre SA, Farace MG, Agami R. Regulation of
the p27(Kip1) tumor suppressor by miR-221 and miR-222 promotes
cancer cell proliferation. EMBO J 2007; 26:3699–3708.
47. Sherr CJ, Roberts JM. Inhibitors of mammalian G1 cyclin-dependent
kinases. Genes Dev 1995; 9:1149–1163.
48. Qian K, Hu L, Chen H, Li H, Liu N, Li Y, Ai J, Zhu G, Tang Z, Zhang H.
Hsa-miR-222 is involved in differentiation of endometrial stromal cells in
vitro. Endocrinology 2009; 150:4734–4743.
49. Gillies JK, Lorimer IA. Regulation of p27Kip1 by miRNA 221/222 in
glioblastoma. Cell Cycle 2007; 6:2005–2009.
50. Galardi S, Mercatelli N, Giorda E, Massalini S, Frajese GV, Ciafre SA,
Farace MG. miR-221 and miR-222 expression affects the proliferation
potential of human prostate carcinoma cell lines by targeting p27Kip1. J
Biol Chem 2007; 282:23716–23724.
51. Visone R, Russo L, Pallante P, De Martino I, Ferraro A, Leone V,
Borbone E, Petrocca F, Alder H, Croce CM, Fusco A. MicroRNAs (miR)-
221 and miR-222, both overexpressed in human thyroid papillary
carcinomas, regulate p27Kip1 protein levels and cell cycle. Endocr Relat
Cancer 2007; 14:791–798.
52. Kato K, Toki T, Shimizu M, Shiozawa T, Fujii S, Nikaido T, Konishi I.
Expression of replication-licensing factors MCM2 and MCM3 in normal,
hyperplastic, and carcinomatous endometrium: correlation with expression
of Ki-67 and estrogen and progesterone receptors. Int J Gynecol Pathol
2003; 22:334–340.
53. Vasudevan S, Tong Y, Steitz JA. Switching from repression to activation:
microRNAs can up-regulate translation. Science 2007; 318:1931–1934.
miRNA REGULATION IN HUMAN ENDOMETRIUM 801
D
ow
nloaded from
 w
w
w
.biolreprod.org. 
